# Lecture 3: Anxiety Disorders ## Unit 2.6: Psychiatry --- ## Learning Objectives By the end of this lecture, students will be able to: 1. Describe the epidemiology and neurobiology of anxiety disorders 2. Explain the diagnostic criteria for generalized anxiety disorder 3. Describe panic disorder and agoraphobia 4. Explain social anxiety disorder and specific phobias 5. Describe the pharmacological treatment of anxiety disorders 6. Explain evidence-based psychotherapy for anxiety --- ## Lecture Outline ### I. Anxiety Disorders Overview Anxiety disorders represent the most common category of psychiatric conditions, affecting approximately thirty percent of individuals over their lifetime. These disorders share features of excessive fear and anxiety along with related behavioral disturbances, but they differ in the types of situations or objects that provoke fear and the cognitive patterns associated with each condition. Women are affected at roughly twice the rate of men, and onset typically occurs during childhood or adolescence, though symptoms can emerge at any age. Comorbidity is exceedingly common, with many patients experiencing multiple anxiety disorders simultaneously alongside depression or substance use disorders. The distinction between normal and pathological anxiety centers on several key parameters. Normal anxiety is proportionate to the actual threat, time-limited in duration, adaptive in promoting survival or performance, and controllable through conscious effort. Pathological anxiety, by contrast, is excessive relative to the actual danger, persists beyond any reasonable timeframe, impairs rather than enhances functioning, and proves difficult or impossible to control despite the individual's best efforts. This distinction is crucial for diagnosis, as some degree of anxiety represents a healthy and protective emotional response. The DSM-5 classification of anxiety disorders includes generalized anxiety disorder characterized by excessive worry about multiple topics, panic disorder featuring recurrent unexpected panic attacks, agoraphobia involving fear of situations where escape might be difficult, social anxiety disorder with fear of social or performance situations, specific phobias targeting particular objects or situations, separation anxiety disorder involving excessive fear of separation from attachment figures, and selective mutism marked by consistent failure to speak in specific social situations despite speaking normally in other contexts. Understanding the conceptual distinction between fear and anxiety provides a foundation for comprehending these disorders. Fear represents a response to an immediate, present threat and activates the fight-or-flight response with intense autonomic arousal. Anxiety, conversely, involves anticipation of a future threat and manifests through worry, hypervigilance, and muscle tension. Most anxiety disorders involve components of both, with fear responses to specific triggers and background anxiety about potential future encounters with feared stimuli. Panel A shows a bar graph of lifetime prevalence rates for different anxiety disorders, with specific phobias highest, followed by social anxiety, GAD, and panic disorder. Panel B illustrates the distinction between normal and pathological anxiety using parallel columns showing proportionate vs excessive responses, time-limited vs persistent duration, adaptive vs impairing outcomes, and controllable vs uncontrollable nature. Panel C displays the DSM-5 classification tree with anxiety disorders branching into generalized, panic, agoraphobia, social anxiety, specific phobias, separation anxiety, and selective mutism. Panel D depicts the conceptual difference between fear (immediate threat, fight-or-flight activation) and anxiety (future threat, worry, hypervigilance) with corresponding brain activation patterns. --- ### II. Neurobiology of Anxiety The neural circuitry underlying anxiety disorders involves a network of interconnected brain regions that regulate threat detection, emotional responses, and top-down control. The amygdala serves as the central hub for fear processing, responsible for detecting threats and initiating fear responses through its connections to hypothalamic and brainstem structures. The prefrontal cortex, particularly the medial and ventromedial regions, provides top-down regulation of amygdala activity and is essential for extinction learning—the process by which learned fears are diminished. The hippocampus contributes contextual information to fear memories, allowing appropriate discrimination between dangerous and safe contexts. The insula processes interoceptive signals, creating awareness of bodily states associated with anxiety, while the anterior cingulate cortex monitors for conflict and regulates fear expression. Multiple neurotransmitter systems contribute to anxiety regulation. GABA, the brain's primary inhibitory neurotransmitter, normally dampens excessive neural activity, and benzodiazepines exert their anxiolytic effects by enhancing GABAergic transmission. Serotonin modulates anxiety through complex effects across multiple receptor subtypes, explaining the efficacy of SSRIs in treating anxiety disorders. Norepinephrine drives arousal and alertness, contributing to hypervigilance and the physical symptoms of anxiety. Glutamate, the primary excitatory neurotransmitter, appears overactive in anxiety states. The hypothalamic-pituitary-adrenal axis, involving corticotropin-releasing hormone and cortisol, mediates stress responses and shows dysregulation in chronic anxiety. The fear conditioning model provides a framework for understanding anxiety disorder development and treatment. In this model, neutral stimuli become associated with aversive outcomes through classical conditioning, leading to fear responses when those stimuli are subsequently encountered. In healthy individuals, extinction learning occurs when the conditioned stimulus repeatedly occurs without the aversive outcome, leading to reduced fear. Anxiety disorders may result from enhanced fear acquisition, impaired extinction learning, or failure to generalize extinction across contexts. This model directly informs exposure-based treatments, which promote extinction learning by having patients repeatedly encounter feared stimuli in safe conditions. Genetic factors contribute significantly to anxiety disorder vulnerability, with heritability estimates of thirty to forty percent across different anxiety disorders. Behavioral inhibition, a temperamental trait characterized by wariness of novelty and unfamiliar situations, represents a significant risk factor identifiable early in childhood. Gene-environment interactions play important roles, with early life stress and adverse experiences interacting with genetic vulnerability to increase anxiety disorder risk. Epigenetic mechanisms may mediate some of these interactions by altering gene expression without changing the underlying DNA sequence. Panel A illustrates the fear circuit in a sagittal brain section, showing the amygdala with connections to the prefrontal cortex (top-down regulation), hippocampus (contextual memory), hypothalamus (autonomic output), and brainstem nuclei (behavioral responses). Panel B displays a neurotransmitter balance diagram with GABA (inhibitory) on one side and glutamate (excitatory) on the other, with serotonin and norepinephrine as modulators, showing how imbalances contribute to anxiety. Panel C demonstrates the fear conditioning and extinction model with acquisition phase (CS + US → CR), fear expression, and extinction phase (CS alone → diminished CR), noting that anxiety disorders represent extinction failure. Panel D shows a flowchart of HPA axis activation from stress through hypothalamus (CRH) to pituitary (ACTH) to adrenal (cortisol) with feedback loops and indication of dysregulation in chronic anxiety. --- ### III. Generalized Anxiety Disorder Generalized anxiety disorder is characterized by excessive anxiety and worry occurring more days than not for at least six months about a variety of events or activities. The worry must be difficult to control and associated with at least three of six somatic and cognitive symptoms in adults, or at least one symptom in children. The disturbance must cause clinically significant distress or impairment in social, occupational, or other important areas of functioning, and the symptoms must not be attributable to substances, medical conditions, or other mental disorders. The six associated symptoms that define the somatic and cognitive manifestations of GAD include restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or experiencing the mind going blank, irritability, muscle tension, and sleep disturbance including difficulty falling asleep, staying asleep, or experiencing restless and unsatisfying sleep. These symptoms must be present for more days than not during the six-month period, and at least three must be endorsed for adult diagnosis. The clinical presentation of GAD involves worry that spans multiple domains rather than focusing on a single concern. Patients typically worry excessively about work performance, family matters, health, finances, and everyday routine matters. The quality of the worry is chronic, difficult to control despite recognition of its excessive nature, and often shifts from topic to topic. Physical symptoms are prominent and frequently bring patients to primary care rather than mental health settings. The onset is often gradual, with many patients reporting that they have been worriers their entire lives, though symptoms may wax and wane in severity over time. The differential diagnosis of GAD requires distinguishing the disorder from normal worry, which does not meet thresholds for excessiveness or impairment. Depression frequently co-occurs with GAD and can cause similar concentration difficulties and sleep problems, but the primary symptoms are mood-related rather than worry-focused. Panic disorder features discrete panic attacks as the prominent concern, while OCD involves specific obsessions and compulsions. PTSD requires trauma exposure and features intrusion and avoidance symptoms. Medical conditions, particularly hyperthyroidism, can mimic GAD and should be excluded through appropriate laboratory testing and physical examination. Panel A presents the DSM-5 diagnostic criteria for GAD in a structured format, emphasizing excessive worry about multiple domains for at least six months with difficulty controlling the worry. Panel B displays the six associated symptoms as icons: a wound-up spring for restlessness, a battery for fatigue, a scattered brain for concentration difficulty, a lightning bolt for irritability, a tense muscle for muscle tension, and a disrupted sleep cycle for sleep problems. Panel C shows a Venn diagram of common worry domains including work, health, family, finances, and daily activities, all overlapping in the center labeled "GAD." Panel D illustrates the differential diagnosis pathway distinguishing GAD from normal worry, depression, panic disorder, OCD, PTSD, and medical conditions like hyperthyroidism. --- ### IV. Panic Disorder A panic attack is defined as an abrupt surge of intense fear or intense discomfort that reaches a peak within minutes. During this time, four or more of thirteen defined symptoms must occur. Panic attacks are not themselves a mental disorder but rather can occur in the context of any anxiety disorder, other mental disorders, or some medical conditions. The distinction between expected panic attacks, which occur in response to specific triggers, and unexpected panic attacks, which arise without obvious cue, is crucial for diagnosis. Panic disorder specifically requires recurrent unexpected panic attacks. The thirteen panic attack symptoms span multiple physiological systems. Cardiovascular symptoms include palpitations, pounding heart, or accelerated heart rate, along with chest pain or discomfort. Respiratory symptoms include sensations of shortness of breath or smothering and feelings of choking. Neurological symptoms include dizziness, unsteadiness, lightheadedness, or faintness, as well as paresthesias including numbness or tingling sensations, and trembling or shaking. Gastrointestinal symptoms include nausea or abdominal distress. Autonomic symptoms include sweating, chills, and hot flashes. Psychological symptoms include fear of dying, fear of losing control or going crazy, and feelings of unreality (derealization) or being detached from oneself (depersonalization). Panic disorder requires recurrent unexpected panic attacks in addition to at least one month of either persistent concern about additional panic attacks or their consequences, or significant maladaptive behavioral change related to the attacks. The concern about panic attacks may manifest as worry about having a heart attack, losing control, or going crazy. Maladaptive behavioral changes may include avoiding activities such as exercise that produce physical sensations similar to panic, or avoiding unfamiliar situations where panic might occur. The symptoms cannot be attributable to substances or medical conditions and are not better explained by another mental disorder. The distinction between expected and unexpected panic attacks has important diagnostic implications. Unexpected attacks occur without any obvious cue or trigger and are characteristic of panic disorder. Expected attacks occur in response to a specific feared object or situation and can occur in other anxiety disorders including specific phobias, social anxiety disorder, and PTSD. A person can have both types of attacks. The key criterion for panic disorder is that at least some attacks must be unexpected, occurring "out of the blue" without any identifiable trigger at the time they occur. Panel A illustrates a panic attack timeline showing the abrupt onset and peak intensity within minutes, followed by gradual resolution over ten to twenty minutes, with symptom count threshold indicated. Panel B displays the thirteen panic attack symptoms organized by system: cardiovascular (heart icon with racing line), respiratory (lungs with shortness of breath), neurological (brain with dizziness and paresthesias), GI (stomach with nausea), autonomic (sweat droplets and temperature symbols), and psychological (thought bubbles with fear of dying, losing control, derealization). Panel C shows the DSM-5 criteria for panic disorder emphasizing recurrent unexpected attacks plus persistent concern or behavioral change for at least one month. Panel D contrasts unexpected attacks (occurring without trigger, characteristic of panic disorder) with expected attacks (occurring in response to specific feared stimuli, characteristic of other anxiety disorders) using before-and-after scenario illustrations. --- ### V. Agoraphobia Agoraphobia involves marked fear or anxiety about two or more of five specific situations: using public transportation such as automobiles, buses, trains, ships, or planes; being in open spaces such as parking lots, marketplaces, or bridges; being in enclosed spaces such as shops, theaters, or cinemas; standing in line or being in a crowd; and being outside of the home alone. The individual fears or avoids these situations because of thoughts that escape might be difficult or help might not be available in the event of developing panic-like symptoms or other incapacitating or embarrassing symptoms such as falling or incontinence. The diagnostic criteria require that agoraphobic situations almost always provoke fear or anxiety and are either actively avoided, require the presence of a companion, or are endured with intense fear or anxiety. The fear or anxiety must be out of proportion to the actual danger posed by the situations and to the sociocultural context. The symptoms must persist for six or more months and cause clinically significant distress or impairment in functioning. The symptoms cannot be better explained by another mental disorder and, if a medical condition is present, the fear must be clearly excessive. The relationship between agoraphobia and panic disorder has evolved in diagnostic classification. In DSM-5, agoraphobia is a separate diagnosis that can occur with or without panic disorder. Many individuals with agoraphobia develop the condition following panic attacks, fearing situations where panic might occur and help would be unavailable. However, agoraphobia can also develop without a history of panic disorder, with individuals fearing the occurrence of other incapacitating symptoms. When both conditions are present, both diagnoses should be given. The clinical impact of agoraphobia varies considerably in severity. Mild cases may involve discomfort in certain situations that are still navigated with effort. Moderate cases involve avoidance of many situations with significant lifestyle restrictions. Severe cases can result in individuals becoming essentially housebound, unable to leave their home without extreme distress or a trusted companion. Safety behaviors, such as only traveling with a companion or only going to familiar locations, maintain the disorder by preventing extinction learning about the safety of avoided situations. Panel A shows icons representing the five agoraphobic situation categories: public transportation (bus, train, plane icons), open spaces (parking lot with car, marketplace), enclosed spaces (store, theater), crowds and lines (multiple human figures in queue), and being outside home alone (house with single figure outside). Panel B illustrates the cognitive pattern underlying agoraphobia: situation entry → thoughts about escape difficulty or unavailable help → fear of panic or embarrassing symptoms → avoidance or endurance with distress → maintenance of fear. Panel C displays the severity spectrum from mild (discomfort but engagement) through moderate (significant avoidance) to severe (housebound), with functional impairment increasing along the spectrum. Panel D shows the relationship between agoraphobia and panic disorder as overlapping but distinct conditions, with some individuals having each alone and others having both. --- ### VI. Social Anxiety Disorder Social anxiety disorder is characterized by marked fear or anxiety about one or more social situations in which the individual is exposed to possible scrutiny by others. Examples include social interactions such as having a conversation or meeting unfamiliar people, being observed while eating or drinking, and performing in front of others such as giving a speech. The individual fears that they will act in a way or show anxiety symptoms that will be negatively evaluated by being humiliating, embarrassing, or leading to rejection or offense to others. The diagnostic criteria require that social situations almost always provoke fear or anxiety, that the social situations are avoided or endured with intense fear or anxiety, and that the fear or anxiety is out of proportion to the actual threat posed by the social situation and the sociocultural context. The symptoms must persist for six months or more and cause clinically significant distress or impairment. The performance only specifier is used when the fear is restricted to speaking or performing in public, representing a more limited form of the disorder. Common feared situations in social anxiety disorder span performance, interaction, and observation domains. Performance situations include public speaking, presentations, and performing music or other activities before an audience. Interaction situations include having conversations, meeting new people, and attending social gatherings. Observation situations include eating or drinking in front of others, writing while being observed, and using public restrooms. The core fears underlying avoidance in all these situations involve negative evaluation by others, humiliation or embarrassment, and rejection. Physical symptoms create a particularly vicious cycle in social anxiety disorder because the symptoms themselves can become the focus of fear. Blushing is visible to others and may be interpreted as evidence of anxiety or embarrassment. Trembling may become apparent when eating, drinking, or writing in front of others. Sweating may be visible and embarrassing. Voice quavering reveals anxiety during speaking. The fear that others will notice these symptoms can actually exacerbate them, creating a self-fulfilling prophecy that maintains the disorder. Panel A displays a three-column layout of social anxiety triggers: performance situations (podium, microphone, presentation screen), interaction situations (conversation bubbles, handshake, group gathering), and observation situations (eating, writing, restroom sign). Panel B illustrates the core fears as a hierarchy with fear of negative evaluation at the top, leading to fears of humiliation/embarrassment and rejection below, all contributing to avoidance behavior at the bottom. Panel C shows the physical symptom cycle: social situation → anxiety → physical symptoms (blushing, trembling, sweating, voice changes) → increased fear of symptom visibility → increased anxiety (circular arrows indicating the reinforcing cycle). Panel D contrasts generalized social anxiety affecting multiple situations with performance-only specifier limited to public speaking and performing, using shaded diagrams of social domains. --- ### VII. Specific Phobias Specific phobia involves marked fear or anxiety about a specific object or situation such as flying, heights, animals, receiving an injection, or seeing blood. The phobic object or situation almost always provokes immediate fear or anxiety and is actively avoided or endured with intense fear or anxiety. The fear or anxiety is out of proportion to the actual danger posed by the object or situation and to the sociocultural context. The fear, anxiety, or avoidance must persist for six months or more and cause clinically significant distress or impairment. DSM-5 specifies several types of specific phobias based on the phobic stimulus. Animal type phobias involve fear of spiders, insects, snakes, dogs, or other animals and are among the most common phobias. Natural environment type includes fears of heights, storms, water, or other natural phenomena. Blood-injection-injury type involves fear of seeing blood, receiving injections, or undergoing invasive medical procedures. Situational type includes fear of flying, elevators, enclosed spaces, or driving. The other type category captures fears that do not fit the other categories, including fear of choking, vomiting, loud sounds, or costumed characters. Blood-injection-injury phobia has unique physiological characteristics that distinguish it from other specific phobias. While other phobias produce pure sympathetic nervous system activation with increased heart rate and blood pressure, blood-injection-injury phobia produces a biphasic response. Initial sympathetic activation is followed by a parasympathetic surge with decreased heart rate and blood pressure, which can result in vasovagal syncope. This fainting response likely has evolutionary origins related to reducing blood loss following injury. Treatment approaches for this subtype include applied tension techniques that maintain blood pressure, in addition to standard exposure methods. Specific phobias are highly prevalent in the population, though many cases are mild and do not significantly impair functioning. Animal phobias are among the most common, followed by height phobia. Fear of flying affects a significant portion of travelers. Blood-injection-injury phobia affects three to four percent of the population and can have significant medical implications when it leads to avoidance of necessary medical care, vaccinations, or blood donation. Treatment with exposure-based approaches is highly effective for specific phobias, with many patients achieving significant improvement in a single extended exposure session. Panel A illustrates the five specific phobia types with representative icons: animal (spider, snake, dog), natural environment (mountain height, storm, waves), blood-injection-injury (syringe, blood drop, medical procedure), situational (airplane, elevator, bridge), and other (vomiting, loud sound, mask). Panel B shows the unique physiological response in blood-injection-injury phobia: initial sympathetic activation (increased HR, BP) followed by parasympathetic surge (decreased HR, BP) leading to possible syncope, contrasted with the sustained sympathetic response in other phobias. Panel C displays a fear hierarchy pyramid used in exposure treatment, with mildly feared situations at the base and most feared at the apex, demonstrating gradual progression. Panel D presents prevalence data as a horizontal bar chart comparing the frequency of different phobia types in the population. --- ### VIII. Pharmacological Treatment of Anxiety SSRIs and SNRIs represent first-line pharmacological treatment for anxiety disorders. Evidence supports their efficacy across generalized anxiety disorder, panic disorder, and social anxiety disorder. All SSRIs have demonstrated effectiveness for anxiety disorders, as have the SNRIs venlafaxine and duloxetine. The choice between agents often depends on side effect profiles, potential drug interactions, and individual patient factors. Specific phobias generally do not respond well to medication and are best treated with exposure therapy. Several important considerations guide SSRI use in anxiety disorders. Delayed onset of therapeutic effect requires four to six weeks for full benefit, and patients must be counseled about this timeframe to maintain adherence. Initial worsening of anxiety is common when starting SSRIs, particularly in panic disorder, necessitating a start low, go slow approach with gradual dose titration. Doses required for anxiety disorders are often higher than those used for depression, and adequate trials should explore the full dosing range. Treatment duration should extend at least twelve months after remission, and medication should be tapered slowly to avoid discontinuation symptoms. Benzodiazepines provide rapid relief of anxiety symptoms but carry significant risks that limit their role in long-term management. Short-term use is appropriate for bridging the gap while SSRIs take effect or for occasional situational use in specific anxiety-provoking situations. Long-term use should generally be avoided due to risks of tolerance, dependence, and withdrawal. Clonazepam and alprazolam are commonly used for panic disorder when benzodiazepines are indicated. Particular caution is warranted in patients with substance use disorders, elderly patients at risk for falls, and those with respiratory conditions. Several other medications play roles in specific anxiety disorder contexts. Buspirone is effective for generalized anxiety disorder, offers no abuse potential, but has a slow onset of action requiring several weeks for effect. Pregabalin is used for GAD in Europe and shows efficacy for social anxiety disorder. Propranolol is useful for performance anxiety on an as-needed basis, blocking the peripheral manifestations of anxiety without affecting cognitive symptoms. Hydroxyzine is an antihistamine with anxiolytic properties used for GAD. Tricyclic antidepressants represent second-line options for panic disorder when first-line agents fail. Panel A shows a treatment algorithm starting with SSRI/SNRI as first-line, with branches for inadequate response leading to dose optimization, switch to alternative SSRI/SNRI, or augmentation strategies. Panel B displays a timeline of SSRI treatment initiation showing potential initial worsening of anxiety in weeks one to two, followed by gradual improvement reaching therapeutic effect at weeks four to six, with the target maintenance period of twelve or more months indicated. Panel C presents a comparison table of medication classes with columns for onset of action, efficacy, abuse potential, and appropriate use context, covering SSRIs/SNRIs, benzodiazepines, buspirone, and beta-blockers. Panel D illustrates benzodiazepine risks using warning symbols: tolerance (escalating dose curve), dependence (chain link), withdrawal symptoms (declining curve with symptoms), and special population cautions (elderly, substance use, respiratory). --- ### IX. Cognitive-Behavioral Therapy for Anxiety Cognitive-behavioral therapy represents the psychotherapeutic gold standard for anxiety disorders, with robust evidence supporting its efficacy across all anxiety disorder diagnoses. The core components of CBT for anxiety include psychoeducation about the nature of anxiety and the specific disorder, cognitive restructuring to identify and challenge anxious thoughts, exposure to feared stimuli and situations, behavioral experiments to test anxious beliefs, and relaxation training including diaphragmatic breathing and progressive muscle relaxation. Exposure therapy is the most essential component of CBT for anxiety disorders. The principle of habituation underlies exposure efficacy—fear naturally decreases with prolonged exposure to a feared stimulus when no actual harm occurs. From a learning perspective, exposure promotes extinction—the formation of new associations indicating that the conditioned stimulus is now safe. Exposure also builds self-efficacy by demonstrating to patients that they can tolerate anxiety and cope with feared situations. Exposure is typically conducted using a hierarchy, beginning with less feared situations and progressing systematically to more challenging exposures as confidence builds. Different types of exposure are employed depending on the nature of the feared stimuli. In vivo exposure involves real-life confrontation with feared objects or situations and is the most powerful form of exposure. Imaginal exposure involves vividly visualizing feared scenarios and is useful when in vivo exposure is impractical or as a preparatory step. Interoceptive exposure involves deliberately inducing feared bodily sensations such as racing heart, dizziness, or breathlessness and is particularly important for panic disorder. Virtual reality exposure uses simulated environments and has growing evidence for specific phobias including flying and heights. Different anxiety disorders benefit from disorder-specific applications of CBT principles. For generalized anxiety disorder, worry exposure involves sustained attention to worst-case scenarios until anxiety habituates, combined with tolerance of uncertainty training. For panic disorder, interoceptive exposure to feared physical sensations is combined with cognitive reappraisal of catastrophic interpretations. For social anxiety disorder, behavioral experiments test predictions about negative evaluation, and video feedback corrects distorted self-perception. For specific phobias, systematic desensitization with gradual exposure or single-session flooding with intensive prolonged exposure are both effective. Panel A displays the core components of CBT for anxiety as interconnected elements in a circle: psychoeducation leads to cognitive restructuring, which connects to exposure, which links to behavioral experiments, which connects to relaxation training, completing the circle back to psychoeducation. Panel B illustrates the exposure therapy principles: habituation shown as a declining anxiety curve during prolonged exposure, extinction shown as new learning that the CS is safe, and self-efficacy shown as increasing confidence across exposure sessions. Panel C depicts the four types of exposure with icons: in vivo (person approaching feared stimulus), imaginal (thought bubble with scenario), interoceptive (body with internal sensations highlighted), and virtual reality (person with VR headset). Panel D shows disorder-specific applications in a four-quadrant layout: GAD (worry exposure, uncertainty tolerance), panic (interoceptive exposure, cognitive reappraisal), social anxiety (behavioral experiments, video feedback), and specific phobia (systematic desensitization, single-session flooding). --- ### X. Special Considerations in Anxiety Disorders Comorbidity is the rule rather than the exception in anxiety disorders, significantly impacting assessment and treatment planning. Depression commonly co-occurs with anxiety disorders, and SSRIs fortunately treat both conditions effectively. Multiple anxiety disorders frequently occur together, and transdiagnostic treatment approaches addressing shared underlying mechanisms can be more efficient than disorder-specific protocols. Substance use disorders require careful attention, with alcohol and benzodiazepines providing short-term relief that perpetuates anxiety long-term, and stimulants and cannabis potentially exacerbating anxiety symptoms. Medical conditions should be addressed as part of comprehensive treatment. The medical differential diagnosis of anxiety symptoms is essential, as numerous medical conditions can present with anxiety manifestations. Hyperthyroidism produces anxiety along with weight loss, tachycardia, and tremor, and should be evaluated with thyroid function tests. Pheochromocytoma causes episodic anxiety with hypertension and should be considered in atypical presentations. Cardiac arrhythmias can cause palpitations mimicking panic attacks and may require cardiac monitoring. Temporal lobe seizures can produce fear as an aura and should be considered when symptoms are stereotyped. Hypoglycemia causes anxiety symptoms related to meal timing. Substance use and withdrawal, particularly from caffeine, alcohol, and sedatives, should be systematically evaluated. Children and adolescents with anxiety disorders present with age-appropriate manifestations that may differ from adult presentations. Anxiety often presents as somatic complaints including stomachaches and headaches rather than worry in younger children. Separation anxiety disorder and specific phobias are particularly common in childhood. Cognitive-behavioral therapy is first-line treatment, with SSRIs added when CBT alone is insufficient. The FDA black box warning regarding suicidality requires careful monitoring when SSRIs are prescribed to youth, though the overall benefit of treatment outweighs risks when anxiety is appropriately severe. Elderly patients with anxiety disorders require special consideration in both assessment and treatment. Anxiety may present primarily with physical symptoms, and late-onset anxiety should prompt thorough medical workup for underlying causes. Medical conditions that can cause anxiety are more common with aging. Treatment considerations include using lower medication doses, avoiding benzodiazepines due to fall risk and cognitive effects, and adapting CBT for any sensory or cognitive limitations. Comorbidity with depression, medical illness, and cognitive impairment is common in this population. Panel A displays a Venn diagram showing overlapping circles for anxiety disorders, depression, substance use, and medical conditions, with the center representing patients with multiple comorbidities requiring integrated treatment. Panel B presents the medical differential diagnosis as a checklist with conditions (hyperthyroidism, pheochromocytoma, cardiac arrhythmia, seizures, hypoglycemia, substance effects) and their distinguishing features. Panel C illustrates developmental considerations across the lifespan, showing childhood presentation (somatic complaints, separation anxiety), adolescent presentation (social anxiety, GAD), adult presentation (full syndromal expression), and elderly presentation (physical symptoms, medical comorbidity). Panel D shows treatment modifications for special populations: children (CBT adapted, SSRI monitoring), elderly (lower doses, avoid benzodiazepines, medical workup), and comorbid patients (integrated treatment, address all conditions). --- ## Summary - Anxiety disorders are the most common psychiatric conditions, affecting thirty percent of individuals over a lifetime, with women affected twice as often as men and onset typically in childhood or adolescence - The neurobiology involves amygdala hyperactivity, prefrontal regulatory deficits, and imbalances in GABA, serotonin, norepinephrine, and glutamate systems - Generalized anxiety disorder features excessive worry about multiple topics for at least six months with at least three associated symptoms including restlessness, fatigue, concentration problems, irritability, muscle tension, and sleep disturbance - Panic disorder requires recurrent unexpected panic attacks plus at least one month of persistent concern about attacks or maladaptive behavioral change - Agoraphobia involves fear and avoidance of situations where escape might be difficult, requiring fear of at least two of five situation types for six months - Social anxiety disorder centers on fear of negative evaluation in social or performance situations, with the performance-only specifier for those with fears limited to public speaking - Specific phobias involve marked fear of specific objects or situations, with blood-injection-injury phobia uniquely featuring a vasovagal response - SSRIs and SNRIs are first-line pharmacotherapy, with delayed onset requiring patient education and higher doses often needed than for depression - Benzodiazepines provide rapid relief but carry dependence risks limiting long-term use - Cognitive-behavioral therapy featuring exposure is the gold-standard psychotherapy, with disorder-specific applications including interoceptive exposure for panic and behavioral experiments for social anxiety --- ## Key Terms | Term | Definition | |------|------------| | Panic attack | Abrupt surge of intense fear reaching peak within minutes with at least four of thirteen defined symptoms | | Agoraphobia | Fear and avoidance of situations where escape might be difficult or help unavailable if panic-like symptoms develop | | Specific phobia | Marked, disproportionate fear of a specific object or situation lasting at least six months | | Exposure therapy | Systematic confrontation with feared stimuli to promote habituation and extinction learning | | Cognitive restructuring | Therapeutic technique involving identification and modification of maladaptive thought patterns | | Habituation | Decreased response to a stimulus with repeated or prolonged exposure | | Interoceptive exposure | Deliberate induction of feared bodily sensations to promote extinction of fear responses | | Safety behavior | Actions taken to prevent feared outcomes that paradoxically maintain anxiety by preventing extinction learning | --- *This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*